Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | KDM5C | P41229 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | EPOR | P19235 | 1/20 | 0.35 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23157519 | 0.98 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23157585 | 0.98 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL158484 | 0.98 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23157565 | 0.98 | CA2 (0.44) | CA2CA12CA1CA4CA9 | |
| Trifluoroacetic Acid SCHEMBL4388146 | 0.91 | NPY1R (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL19172671 | 0.90 | CA2 (0.49) | CA2CA12CA1CA4CA9 | |
| SCHEMBL13581469 | 0.90 | PHF8 (0.46) | CA2CA12CA1CA4CA9 | |
| SCHEMBL23158185 | 0.89 | CA2 (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL17447162 | 0.89 | CA2 (0.40) | CA2CA12CA1CA4CA9 | |
| SCHEMBL15728323 | 0.88 | CA12 (0.46) | CA2CA12CA1CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | ILLUMINA, INC. | 2023-11-09 | — | — | US | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898630-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195498-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| WO-2020126954-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| EP-2352511-A2 | NEUROPEPTIDE-2-RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-20100179093-A1 | Neoropeptide-2-Receptor (Y-2R) Agonists | DANHO WALEED | 2010-07-15 | — | — | US | disclosed |
| WO-2010052144-A2 | NEUROPEPTIDE-2-RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-14 | — | — | WO | disclosed |
| CN-101225094-A | Anthraquinones tetracyclic compound having anticancer activity | TIANJIN HEMEI BIOTECHNOLOGY CO (CN) | 2008-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179093-A1 | Neoropeptide-2-Receptor (Y-2R) Agonists | NPY2R, NPY1R, NPY4R | CA2 2559/4885CA12 3470/4885CA1 4358/4885 |
| US-20230357307-A1 | CLEAVABLE CYCLIC LOOP NUCLEOTIDES FOR NANOPORE SEQUENCING | TENT4A, TENT4B, DNTT | CA2 2628/4885CA12 2524/4885CA1 2230/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | CA2 3666/4885CA12 4075/4885CA1 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.